Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients

Molecular Medicine Reports

Volumn 5, Issue 2, 2012, Pages 517-520

  Nishimura, Takashi ^a   Osaki, Fie ^a   Shioya, Makoto ^a   Imaeda, Hirotsugu ^a   Aomatsu, Tomoki ^a   Takeuchi, Takayuki ^b   Okumura, Yoshiaki ^c   Fujiyama, Yoshihide ^a   Andoh, Akira ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Notogawa Hospital   (Japan)

^c Social Insurance Shiga Hospital   (Japan)

Author keywords

Hemolytic anemia; Hepatitis C virus; Ribavirin

Indexed keywords

HEMOGLOBIN; INORGANIC PYROPHOSPHATASE; INOSINE TRIPHOSPHATE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ALLELE; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ALLELES; ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENE FREQUENCY; GENOTYPE; HEMOGLOBINS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYROPHOSPHATASES; RECOMBINANT PROTEINS; RIBAVIRIN; SEROTYPING;

HEPATITIS C VIRUS;

EID: 84855656374     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.659     Document Type: Article

References (18)

1. Alavian SM, Tabatabaei SV, Keshvari M, et al: Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int 30: 1173-1180, 2010.
2. Welzel TM, Morgan TR, Bonkovsky HL, et al: Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 49: 1847-1858, 2009.
3. Kurosaki M, Tanaka Y, Nishida N, et al: Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 54: 439-448, 2011.
4. Yasui K, Harano Y, Mitsuyoshi H, et al: Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. J Gastroenterol 45: 95-104, 2010.
5. Azakami T, Hayes CN, Sezaki H, et al: Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J Med Virol 83: 1048-1057, 2011.
6. Hadziyannis SJ and Koskinas JS: Differences in epidemiology, liver disease and treatment response among HCV genotypes. Hepatol Res 29: 129-135, 2004. (Pubitemid 38780127)
7. Hadziyannis SJ, Sette H Jr, Morgan TR, et al: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355, 2004.
8. Fried MW, Shiffman ML, Reddy KR, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982, 2002.
9. Manns MP, McHutchison JG, Gordon SC, et al: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001. (Pubitemid 32913521)
10. McHutchison JG, Manns M, Patel K, et al: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123: 1061-1069, 2002.
11. De Franceschi L, Fattovich G, Turrini F, et al: Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 31: 997-1004, 2000. (Pubitemid 30169949)
12. Fellay J, Thompson AJ, Ge D, et al: ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464: 405-408, 2010.
13. Thompson AJ, Santoro R, Piazzolla V, et al: Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 53: 389-395, 2011.
14. Ochi H, Maekawa T, Abe H, et al: ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy - a genome-wide study of Japanese HCV virus patients. Gastroenterology 139: 1190-1197, 2010.
15. Ban H, Andoh A, Imaeda H, et al: The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol 45: 1014-1021, 2010.
16. Livak KJ: Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 14: 143-149, 1999.
17. Russmann S, Grattagliano I, Portincasa P, Palmieri VO and Palasciano G: Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 13: 3351-3357, 2006. (Pubitemid 44669779)
18. Fraser JH, Meyers H, Henderson JF, Brox LW and McCoy EE: Individual variation in inosine triphosphate accumulation in human erythrocytes. Clin Biochem 8: 353-364, 1975.